Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile - Barf, Tjeerd; Covey, Todd; Izumi, Raquel; van de Kar, Bas; Gulrajani, Michael; van Lith, Bart; van Hoek, Maaike; de Zwart, Edwin; Mittag, Diana; Demont, Dennis; Verkaik, Saskia; Krantz, Fanny; et al. (The Journal of pharmacology and experimental therapeutics, 2017)
Keywords: Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides - chemistry; Benzamides - pharmacology; Dose-Response Relationship, Drug; Humans; Jurkat Cells; Leukocytes, Mononuclear - drug effects; Leukocytes, Mononuclear - enzymology; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors - chemistry; Protein Kinase Inhibitors - pharmacology; Protein-Tyrosine Kinases - antagonists & inhibitors; Protein-Tyrosine Kinases - blood; Protein-Tyrosine Kinases - metabolism; Pyrazines - chemistry; Pyrazines - pharmacology; BLK; ITK; CLL; SRC; Txk; YES; FACS; ErbB; XLA; AUC; SRR; FBS; FYN; EGFR (ErbB1); ADCC; LYN; PBS; IL; BMX; PBMC; BCR; FGR; HCK; IMAP; hWB; TEC; PD; JAK; LCK; BTK; PK